The biotech sector has seen some serious momentum lately.



(PFE) - Get Report

, which just bought



for $65 billion dollars, or

Bristol-Myers Squibb

(BMY) - Get Report

, which publicly said that it is looking to invest about $8 billion into the biotech space.

Over the last three months, shares of biotechnology firms


(GERN) - Get Report




are up roughly 200%, compared with a decline in the

S&P 500

of almost 5% and a decline in the Nasdaq Biotechnology Index of about 3%.

So why have both names massively outperformed the boarder market?

To read more,



Don't miss Stockpickr Answers today: Jud Pyle, CFA and chief investment strategist for the Options News Network, will be on Stockpickr Answers today (Monday, Feb. 2) to respond to questions posed by members of the Stockpickr community. Not a member? Join the Stockpickr community today -- for free.

Stockpickr is a wholly owned subsidiary of